The Department of Veterans Affairs announced Aug. 5 a new clinical trial evaluating psilocybin to treat major depression in veterans, including those with concurrent post-traumatic stress disorder, expanding the VA’s foray into psychedelic-assisted therapy.
With more than 17 veterans dying by suicide each day, treatment-resistant depression and PTSD are among the most prevalent and debilitating conditions in the veteran population.
The trial is part of an expanding VA psychedelic research initiative that reflects growing clinical evidence for psilocybin’s therapeutic potential, according to the VA. Psilocybin is currently a Schedule I controlled substance, and VA clinical trials operate under Drug Enforcement Administration research protocols.
The trial follows years of advocacy from veteran service organizations for access to psychedelic-assisted therapy. Organizations including the Multidisciplinary Association for Psychedelic Studies have conducted clinical trials showing promising results for psilocybin and MDMA in treating PTSD and depression.
Conventional antidepressants and psychotherapy do not adequately address symptoms for a significant portion of veterans with treatment-resistant depression. The VA estimates that approximately 30% of veterans with depression do not respond adequately to existing treatments.
A VA-sponsored psilocybin trial is both a scientific milestone and a signal of institutional willingness to explore unconventional treatment modalities for a population disproportionately affected by mental health conditions related to military service.
The trial will be conducted under rigorous clinical protocols with controlled dosing and therapeutic support. Results are expected to inform future VA treatment guidelines.